Thyritope Biosciences

Thyritope Biosciences develops therapeutics targeting thyroid stimulating auto-antibodies, the cause of Graves’ hyperthyroidism and Graves’ orbitopathy. Utilizing molecular evolution technology, the company engineers drugs to absorb these auto-antibodies. This approach aims to move beyond symptom management, directly neutralizing the core autoimmune mechanism driving the disease.

Established around 2014, Thyritope Biosciences resulted from a collaboration between Avalon Ventures and GlaxoSmithKline. Its scientific foundation comes from Dr. Patrick Daugherty, a professor at the University of California, Santa Barbara. His molecular evolution technology offered the insight: directly targeting auto-antibodies causing Graves’ disease, addressing an unmet medical need.

Thyritope Biosciences focuses on patients with Graves’ disease, including hyperthyroidism and orbitopathy. Its vision is to transform treatment by delivering therapeutics neutralizing causative auto-antibodies. This strategy aims to alleviate severe symptoms and offer a targeted solution, envisioning a future where the disease’s underlying mechanism is directly managed.